Male contraceptive future or investigational therapies: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
m (Bot: Removing from Primary care) |
||
| Line 19: | Line 19: | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
[[Category:Contraception for males]] | [[Category:Contraception for males]] | ||
[[Category:Needs content]] | [[Category:Needs content]] | ||
Latest revision as of 22:37, 29 July 2020
|
Male contraceptive Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Male contraceptive future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Male contraceptive future or investigational therapies |
|
FDA on Male contraceptive future or investigational therapies |
|
CDC on Male contraceptive future or investigational therapies |
|
Male contraceptive future or investigational therapies in the news |
|
Blogs on Male contraceptive future or investigational therapies |
|
Risk calculators and risk factors for Male contraceptive future or investigational therapies |
Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.
Methods in development
- Reversible inhibition of sperm under guidance (RISUG) consists of injecting styrene maleic anhydride in dimethyl sulfoxide into the vas deferens and leads to long lasting sterility. A second injection washes out the substance and restores fertility. As of 2007, RISUG is in Phase III of human testing.[1]
- Vas-occlusive contraception consists of partially or completely blocking the vas deferens, the tubes connecting the epididymis to the urethra. While a vasectomy removes a piece of each vas deferens, the intra vas device (IVD) and other injectable plugs only block the tubes until the devices are removed.[1]
- Heat-based contraception involves heating the testicles to a high temperature for a short period of time to prevent the formation of sperm.
- Adjudin, a non-toxic analog of lonidamine which, in tests on rats, has been shown to cause reversible infertility.[2] The drug disrupts the junctions between nurse cells (Sertoli cells) in the testes and forming spermatids. The sperm are released prematurely and never become functional gametes. A new targeted delivery mechanism has made Adjudin much more effective.[3]
- A male hormonal contraceptive combination protocol has been developed, involving injections of Depo-Provera to prevent spermatogenesis, combined with the topical application of testosterone gel to provide hormonal support.[1][4]
- Research has been performed on interference with the maturation of sperm in the epididymis.[5][6]
References
- ↑ 1.0 1.1 1.2 Robert Finn. "Male Contraceptive Methods Are in the Pipeline". Ob.Gyn. News 42:28 May 1, 2007.
- ↑ Dolores D. Mruk and C. Yan Cheng. Sertoli-Sertoli and Sertoli-Germ Cell Interactions and Their Significance in Germ Cell Movement in the Seminiferous Epithelium during Spermatogenesis. Endocrine Reviews (2004) 25 (5): 747-806
- ↑ Mruk DD, Wong CH, Silvestrini B, Cheng CH (2006) A male contraceptive targeting germ cell adhesion Nature Medicine advance access 29 October 2006.
- ↑ Nuzzo R (2006) Beyond condoms: male hormonal contraceptives may finally be on track. Los Angeles Times, 16 October.
- ↑ Turner TT, Johnston DS, Jelinsky SA (2006) Epididymal genomics and the search for a male contraceptive Journal of Molecular and Cellular Endocrinology. Released as an Epub ahead of printing on 1 February 2006.
- ↑ Gottwald U, Davies B, Fritsch M, Habenicht UF (2006) New approaches for male fertility control: HE6 as an example of a putative target Journal of Molecular and Cellular Endocrinology. Released as an Epub ahead of printing on 23 January 2006. lIKE EWE